Brensocatib

BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older.

Side effects, and when to stop

The following adverse reactions are described elsewhere in the labeling:

Dermatologic Adverse Reactions
Gingival and Periodontal Adverse Reactions

Who should not take it

None.

Storing it

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). Store in original container.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Brensocatib; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/brensocatib
APA 7th: sofidex. (2026, August 2). Brensocatib. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/brensocatib
AMA 11th: Brensocatib. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/brensocatib

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.